Emagine Solutions Technology cleared to market VistaScan platform.
Courtney Williams, Emagine Solutions Technology co-founder and chief executive officer, with VistaScan system. Courtesy: Emagine Solutions Technology
Today, Arizona-based medical software device company Emagine Solutions Technology received 510(k) clearance from the U.S. Food and Drug Administration for its VistaScan mobile ultrasound platform that turns a provider’s cell phone or tablet into a portable solution.
“The velocity and complexity of modern medicine is becoming overwhelming, and putting the power of ultrasound into the pockets of clinicians so they can use it for real time diagnosis right at the bedside is liberating and transformative,” said Berndt Schmit, M.D., section chief of emergency radiology at Banner University Medical Center at the University of Arizona and Humanitarian Radiology Development Corps president, in a statement.
According to company information, the platform costs more than 10 times less than a standard ultrasound machine and pairs compatible FDA-cleared ultrasound probes with the VistaScan software application. After downloading the VistaScan app and plugging in one of the three existing probes, clinicians can begin scanning. Through the propriety patent-pending Dynamic Precise Point Measuring System, healthcare providers can use their mobile device’s touchscreen to make precise, pixel-level measurements of an ultrasound image, facilitating diagnostic performance and speed. In addition, providers have several hours of scanning capability without a need to recharge.
Initial applications are expected to be in obstetrics.
“Receiving FDA clearance is excellent validation of our technology and demonstrates the role handheld ultrasound will play in enhancing patient care,” said Courtney Williams, Emagine Solutions Technology co-founder and chief executive officer.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Predicting DCIS Upgrade to Invasive Breast Cancer: Can Contrast-Enhanced Ultrasound Have an Impact?
August 21st 2024Adding two key findings from contrast-enhanced ultrasound to a predictive model of mammography, conventional ultrasound and clinicopathological findings led to a 86.1 percent AUROC for predicting the upgrading of ductal carcinoma in situ to invasive breast cancer, according to new research.
FDA Clears AI-Powered Cardiovascular Ultrasound System from Siemens Healthineers
August 13th 2024Offering a variety of AI features for streamlined workflow and enhanced visualization, the Acuson Origin ultrasound system also features the newly FDA-cleared AcuNav Lumos 4D ICE (intracardiac echocardiography) catheter.